Semper Paratus Acquisition (TVGN) Competitors $1.04 +0.01 (+0.48%) As of 01:16 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TVGN vs. CRMD, OCS, GHRS, TNGX, MNMD, MAZE, NAGE, UPB, DAWN, and KALVShould you be buying Semper Paratus Acquisition stock or one of its competitors? The main competitors of Semper Paratus Acquisition include CorMedix (CRMD), Oculis (OCS), GH Research (GHRS), Tango Therapeutics (TNGX), Mind Medicine (MindMed) (MNMD), Maze Therapeutics (MAZE), Niagen Bioscience (NAGE), Upstream Bio (UPB), Day One Biopharmaceuticals (DAWN), and KalVista Pharmaceuticals (KALV). These companies are all part of the "pharmaceutical products" industry. Semper Paratus Acquisition vs. Its Competitors CorMedix Oculis GH Research Tango Therapeutics Mind Medicine (MindMed) Maze Therapeutics Niagen Bioscience Upstream Bio Day One Biopharmaceuticals KalVista Pharmaceuticals Semper Paratus Acquisition (NASDAQ:TVGN) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk. Do insiders and institutionals hold more shares of TVGN or CRMD? 34.2% of CorMedix shares are held by institutional investors. 73.2% of Semper Paratus Acquisition shares are held by company insiders. Comparatively, 5.3% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Is TVGN or CRMD more profitable? CorMedix has a net margin of 20.81% compared to Semper Paratus Acquisition's net margin of 0.00%. CorMedix's return on equity of 22.57% beat Semper Paratus Acquisition's return on equity.Company Net Margins Return on Equity Return on Assets Semper Paratus AcquisitionN/A N/A -934.56% CorMedix 20.81%22.57%17.02% Does the media prefer TVGN or CRMD? In the previous week, Semper Paratus Acquisition had 2 more articles in the media than CorMedix. MarketBeat recorded 4 mentions for Semper Paratus Acquisition and 2 mentions for CorMedix. CorMedix's average media sentiment score of 1.48 beat Semper Paratus Acquisition's score of 0.85 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Semper Paratus Acquisition 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, TVGN or CRMD? Semper Paratus Acquisition has higher earnings, but lower revenue than CorMedix. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSemper Paratus AcquisitionN/AN/A-$13.73MN/AN/ACorMedix$82.55M9.71-$17.93M$0.2253.70 Do analysts recommend TVGN or CRMD? Semper Paratus Acquisition currently has a consensus target price of $10.00, indicating a potential upside of 856.94%. CorMedix has a consensus target price of $17.14, indicating a potential upside of 45.09%. Given Semper Paratus Acquisition's stronger consensus rating and higher probable upside, analysts plainly believe Semper Paratus Acquisition is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Semper Paratus Acquisition 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has more volatility and risk, TVGN or CRMD? Semper Paratus Acquisition has a beta of -0.73, meaning that its share price is 173% less volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. SummaryCorMedix beats Semper Paratus Acquisition on 9 of the 14 factors compared between the two stocks. Get Semper Paratus Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for TVGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVGN vs. The Competition Export to ExcelMetricSemper Paratus AcquisitionMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$194.92M$3.07B$5.62B$9.56BDividend YieldN/A2.39%4.71%4.03%P/E RatioN/A21.5927.9220.09Price / SalesN/A206.57393.0867.83Price / CashN/A42.5736.3258.75Price / Book-11.618.298.385.82Net Income-$13.73M-$55.06M$3.25B$259.10M7 Day Performance-3.24%-2.18%-1.52%-2.35%1 Month Performance-16.40%16.08%9.12%9.69%1 Year Performance60.77%6.02%35.67%17.11% Semper Paratus Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVGNSemper Paratus Acquisition4.014 of 5 stars$1.05+0.5%$10.00+856.9%+55.2%$194.92MN/A0.003Upcoming EarningsCRMDCorMedix2.7565 of 5 stars$11.98+4.3%$17.14+43.1%+148.7%$779.30M$43.47M54.4630Positive NewsOCSOculis2.248 of 5 stars$17.90+1.1%$35.33+97.4%+56.0%$773.26M$780K-6.782GHRSGH Research1.6863 of 5 stars$14.98+3.3%$32.00+113.6%+22.2%$754.41MN/A-18.9610TNGXTango Therapeutics1.8839 of 5 stars$6.67-2.2%$10.50+57.4%-33.9%$739.25M$42.07M-5.4790News CoverageUpcoming EarningsGap UpMNMDMind Medicine (MindMed)2.1802 of 5 stars$9.68-0.8%$24.00+147.9%+0.4%$737.40MN/A-7.5040MAZEMaze TherapeuticsN/A$16.36-2.7%$25.60+56.5%N/A$736.67M$167.50M0.00121Lockup ExpirationGap UpNAGENiagen Bioscience1.3013 of 5 stars$9.69+4.0%$13.22+36.4%N/A$734.13M$99.60M57.00120UPBUpstream Bio2.0404 of 5 stars$14.34+5.2%$56.50+294.0%N/A$733.21M$2.37M0.0038Upcoming EarningsHigh Trading VolumeDAWNDay One Biopharmaceuticals2.9268 of 5 stars$7.10-1.8%$29.00+308.5%-54.5%$732.85M$131.16M-10.0060Positive NewsUpcoming EarningsKALVKalVista Pharmaceuticals3.9284 of 5 stars$13.57-6.9%$26.29+93.7%-5.0%$728.33MN/A-3.68100 Related Companies and Tools Related Companies CorMedix Competitors Oculis Competitors GH Research Competitors Tango Therapeutics Competitors Mind Medicine (MindMed) Competitors Maze Therapeutics Competitors Niagen Bioscience Competitors Upstream Bio Competitors Day One Biopharmaceuticals Competitors KalVista Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVGN) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Semper Paratus Acquisition Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Semper Paratus Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
